Literature DB >> 30096061

Narrow Band Imaging for Surveillance in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Xiu-He Lv1, Bo-Ling Wang, Guo-Wu Cao.   

Abstract

BACKGROUND: The role of narrow band imaging (NBI) for surveillance colonoscopy in patients with inflammatory bowel disease (IBD) is debatable. We aim to compare NBI versus other endoscopic techniques in surveillance of IBD basing on current evidences.
METHODS: A systematic search of PubMed, Embase, and the Cochrane Library databases was conducted for relevant studies. To assess the detection efficacy, we estimated risk ratios (RRs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes. To assess the differentiation efficacy, we estimated sensitivity and specificity of NBI with reference to histology. All outcome variables were pooled using a random-effects model. Heterogeneity was tested by the Q statistic and I statistic.
RESULTS: A total of 10 studies involving 938 participants were included. Statistically significant differences were not found in the likelihood of detecting patients with dysplastic lesions [RR, 1.11; 95% confidence interval (CI), 0.83-1.48] nor in the likelihood of detecting dysplastic lesions by targeted biopsies (RR, 0.76; 95% CI, 0.51-1.12) between NBI and other techniques, and there was also no difference in the likelihood of detecting dysplastic subtypes. NBI required shorter procedural time compared with other techniques (MD, -10.23; 95% CI, -11.53 to -8.92). The sensitivity and specificity of NBI to differentiate neoplastic lesions from non-neoplastic lesions were 0.64 (95% CI, 0.50-0.77) and 0.74 (95% CI, 0.69-0.79), respectively, and the area under the curve (AUC) was 0.7626.
CONCLUSIONS: Although a shorter procedural time is needed, the clinical application of NBI for both dysplasia detection and neoplasia differentiation in IBD is not superior to other endoscopic techniques.

Entities:  

Year:  2019        PMID: 30096061     DOI: 10.1097/MCG.0000000000001101

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  3 in total

1.  Aggressive Colorectal Cancer in an Inflammatory Bowel Disease Patient following Treatment with Vedolizumab: A Case Report.

Authors:  Catarina Nascimento; Helena Oliveira; Catarina Fidalgo; Lídia Roque Ramos; Luísa Glória; Joana Torres
Journal:  GE Port J Gastroenterol       Date:  2021-07-27

Review 2.  Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Diseases: Chromoendoscopy or Non-Chromoendoscopy, That Is the Question.

Authors:  Roberto Gabbiadini; Ferdinando D'Amico; Alessandro De Marco; Maria Terrin; Alessandra Zilli; Federica Furfaro; Mariangela Allocca; Gionata Fiorino; Silvio Danese
Journal:  J Clin Med       Date:  2022-01-20       Impact factor: 4.241

Review 3.  Evolving roles of magnifying endoscopy and endoscopic resection for neoplasia in inflammatory bowel diseases.

Authors:  Shintaro Akiyama; Taku Sakamoto; Joshua M Steinberg; Yutaka Saito; Kiichiro Tsuchiya
Journal:  World J Gastrointest Oncol       Date:  2022-03-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.